Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Colorectal Neoplasms 15Rectal Neoplasms 14Colonic Neoplasms 14Stomach Neoplasms 10Ovarian Neoplasms 7Carcinoma, Hepatocellular 5Gastrointestinal Stromal Tumors 4Carcinoma, Renal Cell 4Peritoneal Neoplasms 3Pancreatic Neoplasms 3Liver Neoplasms 3Neoplastic Cells, Circulating 2Neoplasms 2Kidney Neoplasms 2Fallopian Tube Neoplasms 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Endometrial Neoplasms 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Urinary Incontinence 1Surgical Wound Infection 1Sexual Dysfunction, Physiological 1Prostatic Neoplasms 1Polycystic Ovary Syndrome 1Pancreatic Neuroendocrine Tumors 1Ovarian Cysts 1Obesity, Morbid 1Neoplasm Metastasis 1

Interventions

Oxaliplatin 11Mitomycin 10Leucovorin 7Irinotecan 6Fluorouracil 6Hyperthermic Intraperitoneal Chemotherapy 5Capecitabine 4Surveys and Questionnaires 3Cytoreduction Surgical Procedures 3Cisplatin 3dehydroftorafur 2Trastuzumab 2Thalidomide 2Mitozytrex 2Melphalan 2Interleukin-12 Subunit p35 2Floxuridine 2Doxorubicin 2Cetuximab 2Biopsy 2tipifarnib 1surufatinib 1sodium thiosulfate 1sintilimab 1nintedanib 1nilotinib 1motexafin lutetium 1irinotecan sucrosofate 1entinostat 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Appendiceal Neoplasms × Laparoscopy × Clear all
NCT05185947 2026-05-29

Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
21 enrolled 21 charts
BreastGastrointestinalGynecologic

Appendiceal Neoplasms, Breast Neoplasms, Genital Neoplasms, Female, Ovarian Neoplasms, Peritoneal Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡